Stocktoria
FEMASYS INC FEMY
FEMASYS INC (FEMY) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $2.3M at a -812.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.32 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| FEMY | FEMASYS INC | 2/9 | — | — | — |
| USAQ | QHSLab, Inc. | 4/9 | -1.02 | — | — |
| OSRH | OSR Health, Inc. | — | 1.04 | — | — |
| EBRCZ | EBR Systems, Inc. | 2/9 | -12.31 | — | — |
| INBS | INTELLIGENT BIO SOLUTIONS INC. | 2/9 | — | — | — |
| EMED | Electromedical Technologies, Inc | 4/9 | — | — | — |
| AURX | Nuo Therapeutics, Inc. | 3/9 | — | — | — |
About FEMASYS INC
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
FAQ
Is FEMY financially healthy?
FEMASYS INC's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does FEMY pay a dividend?
No, FEMASYS INC does not currently pay a dividend.
How profitable is FEMY?
In FY2025, FEMASYS INC had a net margin of -812.3% and a return on equity of -317.4%.
What is the analyst price target for FEMY?
The average Wall-Street price target for FEMASYS INC is $63.33, about 2595.0% above the recent price.
Is FEMY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on FEMASYS INC: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.